STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is reporting that the company’s subsidiary NeuroVive Pharmaceutical Asia Ltd., whose registered office is in Hong Kong, has signed a financial advisory agreement with Yuanta Securities Co., Ltd., Taiwan’s leader in IPOs. This agreement is the first phase of a process with the objective of an IPO of NeuroVive’s subsidiary on the Taiwanese stock exchange within two to three years.
Help employers find you! Check out all the jobs and post your resume.
